NEW YORK (GenomeWeb) – The Centers for Medicare & Medicaid Services' recent draft national coverage determination for FoundationOne CDx and similar next-generation sequencing tests has some lab industry players concerned that if the policy is finalized, it would significantly limit late-stage cancer patients' access to critical testing.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.